Exjade 125 MG Tablet for Oral Suspension

RxCUI
616159
RxNorm name
Exjade 125 MG Tablet for Oral Suspension
Display name
Exjade 125 MG Tablet for Oral Suspension
Full name
Exjade 125 MG Tablet for Oral Suspension
Term type
SY
Status
DailyMed mapping
Updated
2026-06-04 23:38:53

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
ExjadeDEFERASIROXNovartis Pharmaceuticals Corporation3495a70c-870c-4968-940e-8baea152cf852026-01-28Boxed warning, Warnings, Adverse reactionsExact identifier
rxcui: 616159

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 1 matching rows.

Set ID, RxNorm mappings, Terms table
Set IDRxNorm mappingsTermsSPL versionLabelEffective
3495a70c-870c-4968-940e-8baea152cf85EXJADE 125 MG Tablet for Oral Suspension [PSN] · deferasirox 125 MG Tablet for Oral Suspension [Exjade] [SBD] · Exjade 125 MG Tablet for Oral Suspension [SY]349These highlights do not include all the information needed to use EXJADE safely and effectively. See full prescribing information for EXJADE. EXJADE ® (deferasirox) tablets, for oral suspension Initial U.S. Approval: 200520260128